Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
ClinicalTrials.gov; 19/10/2021; TrialID: NCT05087277
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05087277
ABSTRACT
Condition
COVID-19Primary outcome:
Neutralizing capabilities to variant COVID-19 after primary and booster vaccination;Titer of Subclass of IgG after primary and booster vaccinationCriteria
Inclusion Criteria
- Between the ages of 18 and 59
- Healthy
- No vaccination with COVID-19 before become participant
- Agreed to take a blood sample
Exclusion Criteria
- who cannot take the COVID-19 vaccine due to some personal reasons
- history of SARS-CoV, SARS-CoV-2, or Middle East respiratory syndrome infection
- high-risk epidemiology history within 14 days before enrolment (eg, travel or
residence history in communities with case reports, or contact history with someone
infected with SARS-CoV-2)
- axillary temperature of more than 37·0?
- history of allergy to any vaccine component.
Coleções:
Registros de ensaios clínicos
Base de dados:
ICTRP
Tópicos:
Vacinas
/
Variantes
Ano de publicação:
2021
Tipo de documento:
Clinical Trial Register
Similares
MEDLINE
...
LILACS
LIS